- Adjuvant chemotherapy (ACT)—typically 6 months of oral 5-FU (+ folinate), oral/infusional 5-FU, and oxaliplatin—was associated with greater recurrence-free survival (RFS) and OS after curative surgery in patients with stage IV colorectal cancer (CRC).
Why this matters
- ACT has shown benefit in stage III disease but few studies have been performed in stage IV CRC.
- Retrospective analysis (n=155).
- Median follow-up time was 54.3 months.
- Funding: Japan Society for the promotion of Science, Project for Cancer Research and Therapeutic Evolution.
- AC was administered to 57% of patients who underwent surgery between 2003-2010, and 76% between 2011 and 2017 (P=.015).
- 51 patients received 5-FU (and folinate), 30 mFOLFOX6, 15 oxaliplatin/capecitabine, and 7 oxaliplatin/S-1.
- After propensity-score matching, ACT was associated with improved 2-year (28% vs 19%) and 5-year RFS (25% vs 16%; P<.001>
- 2- and 5-year OS were likewise improved (88% vs 76%; 66% vs 46%; P=.0008).
- Retrospective study.
- Small sample size.
- Japanese population.